Unidade Local de Saúde de Lisboa Ocidental
Carnaxide, Lisbon District, 2790-134, Portugal
Location status: Recruiting
NCT Number: NCT07597291
The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are:
* How have management strategies and clinical outcomes for cardiogenic shock evolved over time? * How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population?
Researchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care.
Participants will:
* Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced). * Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay. * Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Carnaxide, Lisbon District, 2790-134, Portugal
Location status: Recruiting
The Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK) is hybrid (retrospective and prospective), observational registry designed to evaluate the clinical performance, therapeutic management, and outcomes of patients presenting with cardiogenic shock (CS).
Contemporary CS management has evolved beyond correcting macro-hemodynamic parameters. CS is now recognized as a highly dynamic, systemic syndrome characterized by microvascular hypoperfusion, systemic inflammatory response syndrome (SIRS), endothelial dysfunction, and profound neurohormonal and metabolic derangements. To capture this complexity, the COR-SHOCK registry systematically integrates granular, real-world data reflecting these pathophysiological axes. This includes laboratory evaluation, and advanced invasive hemodynamic profiling via pulmonary artery catheterization (Swan-Ganz).
Registry Procedures and Quality Assurance Plan
To ensure high-quality data collection and compliance with scientific standards, the registry implements the following procedures:
The Steering Committee, led by the Principal Investigator, oversees the registry's operations. Internal data quality audits are conducted semi-annually to review enrollment rates, evaluate protocol adherence, and identify systematic data entry discrepancies.
Data is transcribed from electronic health records into a dedicated electronic database. The entry platform utilizes programmed range validation and consistency rules (e.g., preventing physiological out-of-range values for hemodynamics and laboratory results, and enforcing logical chronological order for clinical events, such as ensuring discharge dates succeed admission dates).
To guarantee data accuracy and completeness, a designated researcher who is not directly involved in the primary data entry performs random source data verification on 10% of all registry entries. This process involves cross-referencing database records with original paper and electronic health records.
A comprehensive data dictionary has been established, detailing every variable collected. It defines clinical terminology, laboratory reference ranges, and standardized categorization rules.
Formal SOPs govern all key registry processes, including:
The registry aims to include approximately 750 to 800 patients. This target is calculated based on historical admission rates at the center, comprising a retrospective cohort of approximately 500 patients (2017-2025) and a prospective recruitment target of 80 to 100 patients annually over a 2-to-3-year period. This sample size provides sufficient statistical power to characterize temporal trends, evaluate subset populations (e.g., mechanical circulatory support, specific etiologies), and perform robust multivariable risk modeling.
Statistical Analysis Plan (SAP) Descriptive statistics will characterize the study population. Continuous variables will be presented as mean ± standard deviation (SD) or median with interquartile range (IQR), based on normality (assessed via Shapiro-Wilk test). Categorical variables will be expressed as frequencies and percentages.
To evaluate management and outcome trends over the years:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-Cardiogenic shock according to the following criteria:
Cardiac disorder resulting in hypotension, defined as at least one of the following:
AND
Evidence of tissue hypoperfusion, defined by the presence of at least one of the following:
AND
Clinical presentation judged to be primarily attributable to a cardiac etiology.
Exclusion criteria
Time frame: From date of hospital admission to 30 days after admission
The proportion of patients presenting with cardiogenic shock who die from any cause during the first 30 days after admission
Time frame: At 1 year post-index admission.
The rate of all-cause mortality evaluated after the index admission. Survival status will be determined via electronic medical records or the national registry ("last seen alive" verification).
Time frame: From date of hospital admission to 30 days after admission
The proportion of patients experiencing major bleeding events up to 30 days after admission. Major bleeding is defined according to the Bleeding Academic Research Consortium (BARC) classification as Type 3 (including 3a, 3b, and 3c) or Type 5 (fatal bleeding).
Time frame: From date of hospital admission to 30 days after admission
Thrombotic/ischemic events are defined using the 3-point Major Adverse Cardiovascular Events (3P-MACE) composite, which includes cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke at 30 days after admission.
Time frame: Up to 1 year post-index admission.
The percentage of patients transitioning to advanced, long-term therapeutic options, specifically durable Left Ventricular Assist Devices (LVAD, e.g., HeartMate 3) or undergoing heart transplantation as a bridge or destination therapy.
Interested in participating?
Request InfoHospital de Santa Cruz, Portugal
Other
Cardiovascular Outcomes Registry in Cardiogenic SHOCK
Acronym: COR-SHOCK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07354568
Bypass, Cardiopulmonary, Cardiogenic Shock Acute
Amiens, Somme, France
View Trial DetailsNCT07323238
Cardiogenic Shock, Cardiogenic Shock Acute
Hong Kong, Shatin
View Trial DetailsNCT07090382
Acute Coronary Syndrome, Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)
Bratislava, Slovakia
View Trial DetailsNCT06728605
Cardio-pulmonary Bypass, Cardiogenic Shock Acute
Nanjing, Jiangsu, China
View Trial Details